Andere Sprachen Cadrenal Therapeutics, Inc.

Aktien

A3DTQ8

US1276361086

CVKD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 22.05.2024			% 5 Tage	% 1. Jan.
0,4127 ^USD	-1,74 %		-6,92 %	-44,22 %

09.05.	Cadrenal Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
09.04.	Cadrenal Therapeutics erhält FDA Orphan Drug Designation für Tecarfarin zur Prävention von Thromboembolien und Thrombosen bei Patienten mit LVADs, RVADs, biventrikulären Assistenzsystemen und totalen Kunstherzen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	09.05.
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	11.04.
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09.04.
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin	09.04.
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09.04.
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall	12.03.
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11.03.
CADRENAL THERAPEUTICS TO PARTICIPATE AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS CONFERENCE	27.02.
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	26.02.
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	08.02.
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer	08.02.
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	24.01.
Certain Warrants of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20.01.
Certain Common Stock of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20.01.
Certain Stock Options of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20.01.
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	04.01.
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	19.12.
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	12.12.
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023	30.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cadrenal Therapeutics, Inc.

Aktien

A3DTQ8

US1276361086

CVKD

Andere Sprachen

Filter